MolecuLight to Unveil Cutting-Edge Wound Imaging Tech at VAM 2025
MolecuLight Inc., acclaimed for its pioneering work in point-of-care fluorescence imaging technology, will be participating in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM) 2025, scheduled from June 4-7, in New Orleans, Louisiana. This premier event draws vascular surgeons and healthcare professionals from around the world, focusing on the latest advancements in vascular health.
At Booth #654, MolecuLight aims to demonstrate its state-of-the-art DX™ device, which offers clinicians real-time insights into wound characteristics. This device not only detects the presence of infection-causing bacteria but also provides precise digital wound measurements and novel thermal imaging features that visualize temperature changes in wounds.
The importance of such technology is underscored in the clinical setting. Infections in wounds can lead to severe complications, and timely detection is crucial for effective treatment. The use of MolecuLight’s DX™ device allows physicians to make informed decisions on wound management quickly and based on objective evidence, ultimately improving patient outcomes. Clinical studies have demonstrated that the integration of this technology can significantly influence treatment plans including the debridement of bacteria and biofilms, highlighting its value in managing complex wounds effectively.
In connection with this event, MolecuLight also celebrates Dr. Alisha Oropallo’s recent achievement—she has received the Society for Vascular Surgery Section on Ambulatory Vascular Care (SAVC) Presentation Award for her abstract titled, "An objective comparative study of non-surgical cleansing techniques and cleanser types in bacterial burden management." Dr. Oropallo will present her award-winning research on June 6th, shedding light on the critical need for objective data in wound care—a principle that aligns closely with MolecuLight’s mission of empowering clinicians with actionable insights.
"Participating in the SVS Vascular Annual Meeting gives us an incredible opportunity to connect with leading experts in vascular surgery," stated Anil Amlani, CEO of MolecuLight. He added, "We are proud that Dr. Oropallo’s research, which emphasizes the importance of objective assessment in wound care, will be highlighted at such a prestigious meeting."
The event serves not just as a platform for exhibiting innovative technology but also for networking and exchanging knowledge among healthcare professionals dedicated to advancing the field of vascular surgery. Attendees will have the chance to experience first-hand how MolecuLight's wound imaging technology can elevate the efficiency of clinical practices, thereby contributing to better patient care and health outcomes.
In summary, MolecuLight’s participation at the SVS Vascular Annual Meeting 2025 stands as a testament to its commitment to improving wound management through innovation. With the insights and tools provided by the DX™ device, clinicians will be better equipped to tackle the challenges associated with wound care, enhancing the quality of care provided to patients. As the event draws closer, anticipation builds for the contributions that will be presented, further advancing the landscape of vascular health.
For more information on MolecuLight’s offerings and to discover how the DX device enhances clinical practices, attendees are encouraged to visit Booth #654 during the SVS Vascular Annual Meeting.
For sales or media inquiries regarding MolecuLight, please reach out to Danielle Dunham, Director of Product, at +1.416.542.5524 or visit MolecuLight's website.
At Booth #654, MolecuLight aims to demonstrate its state-of-the-art DX™ device, which offers clinicians real-time insights into wound characteristics. This device not only detects the presence of infection-causing bacteria but also provides precise digital wound measurements and novel thermal imaging features that visualize temperature changes in wounds.
The importance of such technology is underscored in the clinical setting. Infections in wounds can lead to severe complications, and timely detection is crucial for effective treatment. The use of MolecuLight’s DX™ device allows physicians to make informed decisions on wound management quickly and based on objective evidence, ultimately improving patient outcomes. Clinical studies have demonstrated that the integration of this technology can significantly influence treatment plans including the debridement of bacteria and biofilms, highlighting its value in managing complex wounds effectively.
In connection with this event, MolecuLight also celebrates Dr. Alisha Oropallo’s recent achievement—she has received the Society for Vascular Surgery Section on Ambulatory Vascular Care (SAVC) Presentation Award for her abstract titled, "An objective comparative study of non-surgical cleansing techniques and cleanser types in bacterial burden management." Dr. Oropallo will present her award-winning research on June 6th, shedding light on the critical need for objective data in wound care—a principle that aligns closely with MolecuLight’s mission of empowering clinicians with actionable insights.
"Participating in the SVS Vascular Annual Meeting gives us an incredible opportunity to connect with leading experts in vascular surgery," stated Anil Amlani, CEO of MolecuLight. He added, "We are proud that Dr. Oropallo’s research, which emphasizes the importance of objective assessment in wound care, will be highlighted at such a prestigious meeting."
The event serves not just as a platform for exhibiting innovative technology but also for networking and exchanging knowledge among healthcare professionals dedicated to advancing the field of vascular surgery. Attendees will have the chance to experience first-hand how MolecuLight's wound imaging technology can elevate the efficiency of clinical practices, thereby contributing to better patient care and health outcomes.
In summary, MolecuLight’s participation at the SVS Vascular Annual Meeting 2025 stands as a testament to its commitment to improving wound management through innovation. With the insights and tools provided by the DX™ device, clinicians will be better equipped to tackle the challenges associated with wound care, enhancing the quality of care provided to patients. As the event draws closer, anticipation builds for the contributions that will be presented, further advancing the landscape of vascular health.
For more information on MolecuLight’s offerings and to discover how the DX device enhances clinical practices, attendees are encouraged to visit Booth #654 during the SVS Vascular Annual Meeting.
For sales or media inquiries regarding MolecuLight, please reach out to Danielle Dunham, Director of Product, at +1.416.542.5524 or visit MolecuLight's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.